Loading...
ABMD logo

Abiomed, Inc.Informe acción NasdaqGS:ABMD

Capitalización bursátil US$17.2b
Precio de las acciones
n/a
1Y8.2%
7D0.005%
1D0.06%
Valor de la cartera
​
Ver

Abiomed, Inc.

Informe acción NasdaqGS:ABMD

Capitalización de mercado: US$17.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed (ABMD) Resumen de Acciones

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. Saber más

Análisis fundamental de ABMD
Puntuación del snowflake
Valoración0/6
Crecimiento futuro1/6
Rendimiento pasado4/6
Salud financiera6/6
Dividendos0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 13.08%

Los beneficios aumentaron un 78.9% el pasado año

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 2.5% al año durante los próximos 3 años

Precio de las acciones volátil durante los últimos 3 meses en comparación con el mercado US

Grandes partidas extraordinarias que afectan a los resultados financieros


ABMD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW478,064 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
478,064 investors already sharing narratives
View all narratives

Competidores de Abiomed, Inc.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Abiomed
Precios históricos de las acciones
Precio actual de la acciónUS$381.02
Máximo en las últimas 52 semanasUS$381.99
Mínimo de 52 semanasUS$219.85
Beta1.4
Cambio en 1 mes0.86%
Variación en 3 meses55.18%
Cambio de 1 año8.18%
Variación en 3 años125.10%
Variación en 5 años103.31%
Variación desde la OPV6,385.45%

Noticias y actualizaciones recientes

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.

Recent updates

Seeking Alpha • Oct 17

Abiomed's Impella low profile sheath gets FDA clearance

The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Abiomed's (NASDAQ:ABMD) Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr, the company said in a statement on Monday. Abiomed added that due to its smaller size and other advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, and reduce procedural steps. The company said that it will begin a phased roll-out of the Impella Low Profile Sheath this quarter. The heart pump Impella CP with SmartAssist is approved to treat certain patients with advanced heart failure who are undergoing percutaneous coronary interventions, such as stenting or balloon angioplasty, to reopen blocked coronary arteries, according to the company.
Seeking Alpha • Sep 28

Abiomed: Correction Offers Good Buying Opportunity

Summary Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace. The company’s OXY-1 System cardiopulmonary support device has strong growth prospect. The company’s revenue will grow at a CAGR of high-single digits in the long term, which will drive the company’s share price significantly higher in the next five years. Abiomed's (ABMD) micro heart pumps enjoy rising demand in the cardiovascular marketplace. I expect the company's Impella range of micro heart pumps will drive the company's long-term revenue growth significantly, and its Impella product pipeline will support long-term revenue growth as well. Long-term growth-oriented investors can buy the company's shares around the current price to maximize their profit. Abiomed develops heart pump products and oxygenation products for patients who are suffering from severe heart disease and in need of hemodynamic support. Its products are used in cath lab by interventional cardiologists and in the heart surgery suite by cardiac surgeons. The company's heart pump products work by improving blood flow and/or performing the pumping function of the heart. Its oxygenation products work by providing sufficient oxygenation to respiratory failure patients. Growth Drivers Impella Heart Pumps Abiomed's Impella micro heart pump product line is its main growth driver. Impella is a percutaneous heart pump that is used to treat CHD (coronary heart disease), and high-risk PCI (percutaneous coronary intervention). Impella has variants which are Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP. These pumps beat competitive products, such as intra-aortic balloon pumps (IABPs) and the TandemHeart device, due to the following reasons: Impella helps CHD and PCI patients maintain proper blood circulation in a better way. Impella offers continued function irrespective of timing or trigger. These pumps offer stability to patients despite the presence of arrhythmias. These pumps can pump up to 2.5 to 6 liters of blood per minute, which provides better cardiac output. According to a report: The heart pump device market is projected to reach USD 5.5 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 21.6% from 2021 to 2026. Promising product pipeline, increasing number of product approvals and emerging markets are expected to offer growth opportunities in the market during the forecast period. Due to the strong growth prospects of the heart pump market, Abiomed's revenue will continue to grow rapidly in the next five years. OXY-1 System Abiomed's OXY-1 System, which is a compact cardiopulmonary support system, is the company's another growth driver. The system offers respiratory assistance to patients suffering from cardiogenic shock combined with respiratory failure. The machine's oxygen concentrator and pump provide oxygenation to venous blood, and as a result, patients get significant respiratory support. The device performs well in the competitive environment and beat competitor products such as traditional ECMO (extracorporeal membrane oxygenation) machines due to its capability to provide uniform blood flow and superior respiratory support. I expect the device will support Abiomed's long-term revenue growth which primarily comes from Impella. Competition The heart pump industry is characterized by tremendous competition. Abiomed's competitors in this industry include Abbott Laboratories (ABT), Medtronic (MDT), Edwards Lifesciences (EW), Boston Scientific (BSX), LivaNova (LIVN), and Terumo Corporation (TRUMF). Abiomed competes with these companies on the basis of developing innovative heart pump devices, continuity in new product development, and advanced 24 x 7 hospital support. Abiomed's primary competitive advantage is that its current strategy of developing devices in the area of circulatory care is supported by substantial expertise in developing heart pump devices. As a result, the company's heart pump devices enjoy significant demand in the marketplace. The company intends to continue to use its expertise in developing additional circulatory support devices and making enhancements to existing devices, which will support its future revenue growth. The company's another competitive advantage is that its Impella micro heart pump is the only FDA approved heart pump for high-risk PCI, cardiogenic shock, and right ventricular failure. As a result, Impella and its forthcoming variants will continue to drive Abiomed's revenue growth. First Quarter 2023 Financial Results Abiomed reported first quarter 2023 revenue of $277 million, an increase of 10% year-over-year, compared to $253 million in the prior fiscal year period. Non-GAAP net income per diluted share came in at $1.25, an increase of 13.6% year-over-year, compared to $1.10 in the prior fiscal year period. The company delivered strong results for the first quarter of fiscal 2023. Top line grew driven by robust sales across the U.S., Europe and Japan. The company's heart pump product line is witnessing growing adoption since it addresses the challenge of treating heart disease in multiple emergency patient populations in the cath lab and surgical suite. This is driving the company's revenue growth. The company's bottom line grew driven by strong patient utilization across the three regions mentioned above. Abiomed 2.0, the new Abiomed with unparalleled focus on innovating heart and lung repairing devices amid hindrances such as hospital labor shortages, supply chain constraints and contrast media shortages, will boost the company's top and bottom line growth in the next five years. I expect the company's revenue will grow at a CAGR of high single-digits in this time frame.
Seeking Alpha • Sep 16

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Abiomed (NASDAQ:ABMD) said on Friday it had received two approvals from the U.S. Food and Drug Administration related to clinical research of Impella heart pumps for acute myocardial infarction (AMI) cardiogenic shock or heart attack. The FDA has approved the on-label RECOVER IV trial for AMI cardiogenic shock patients. RECOVER IV is a trial that is designed to to achieve a Class I guideline recommendation for Impella use in AMI cardiogenic shock. The FDA has also approved and closed Impella’s prospective AMI cardiogenic shock post-approval study, dubbed Recover III. This study gathered real-world evidence on AMI cardiogenic shock patients treated with Impella between 2017–2019, collecting detailed data including stages of cardiogenic shock, cardiac output and timing of implantation.
Seeking Alpha • Aug 03

Abiomed FQ1 2023 Earnings Preview

Abiomed (NASDAQ:ABMD) is scheduled to announce FQ1 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $1.06 (-3.6% Y/Y) and the consensus Revenue Estimate is $276.46M (+9.4% Y/Y). Over the last 2 years, ABMD has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • May 17

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

ABMD had a decent quarter where revenues grew nicely but profits languished due to sudden growth in R&D spend. Companies like ABMD have to expense R&D, which is not a problem, but a lack of profit growth isn't great given its valuation. The multiple doesn't offer much of a margin of safety, but we recognise the premier product portfolio. Overall, there is a defensive angle for the stock given rate increases, but the valuation is too much of a concern.
Seeking Alpha • Jan 24

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Abiomed is a company with a superb product in the mid-market space while what appears on the surface is an extremely high multiple. While the multiple appears high at first, it does actually reflect the profile of the company on a more normalised basis, where it is currently experiencing headwinds. The secular outlook is obviously intact, but given the high multiple and the unknown length of the medium-term headwinds, it is not an especially compelling opportunity.
Seeking Alpha • Sep 10

Abiomed: Impella Will Continue To Drive Revenue Growth

Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.
Seeking Alpha • Jul 13

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed has commenced its path to recovery on the charts, following a big hit in April this year. Key tension points for ABMD's share price lie in its Impella sales volume, which continues to gain traction sequentially as we walk through this year. Shares are trading at a premium to historical averages and to the peer group, thus balancing the investment case. Nonetheless, we are bullish on ABMD shares and see an investment debate that is skewed in investors' favour. Here, we present all of the necessary moving parts in the investment debate for the benefit of investors' own reasoning.

Rentabilidad de los accionistas

ABMDUS Medical EquipmentMercado US
7D0.005%2.7%0.6%
1Y8.2%-11.6%20.1%

Rentabilidad vs. Industria: ABMD superó a la industria US Medical Equipment, que obtuvo un rendimiento del -11.6% el año pasado.

Rentabilidad vs. Mercado: ABMD superó al mercado US, que obtuvo un rendimiento del 20.1% el año pasado.

Volatilidad de los precios

Is ABMD's price volatile compared to industry and market?
ABMD volatility
ABMD Average Weekly Movement14.6%
Medical Equipment Industry Average Movement8.5%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Precio estable de las acciones: El precio de las acciones de ABMD ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ABMD ha aumentado de 9% a 15% en el último año.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
19812,003Mike Minoguewww.abiomed.com

Resumen de fundamentos de Abiomed, Inc.

¿Cómo se comparan los beneficios e ingresos de Abiomed con su capitalización de mercado?
Estadísticas fundamentales de ABMD
Capitalización bursátilUS$17.19b
Beneficios(TTM)US$266.76m
Ingresos (TTM)US$1.07b
64.4x
Ratio precio-beneficio (PE)
16.0x
Ratio precio-ventas (PS)

¿Está ABMD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ABMD
IngresosUS$1.07b
Coste de los ingresosUS$200.59m
Beneficio brutoUS$873.51m
Otros gastosUS$606.74m
BeneficiosUS$266.76m

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)5.91
Margen bruto81.32%
Margen de beneficio neto24.84%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado ABMD a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2022/12/24 16:49
Precio de las acciones al final del día2022/12/21 00:00
Beneficios2022/09/30
Ingresos anuales2022/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Abiomed, Inc. está cubierta por 21 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Lawrence NeiborBaird
Jan WaldBenchmark Company
Isaac RoGoldman Sachs